Phase 3 N=2,031 HIV Testing & Womens Attitudes on HIV Vaccine Trials
HIV
Primary: Number of Participants Who Accepted Rapid HIV Testing. — 458; 401; 410; 418 participants — p=0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=604 Efficacy of Nalmefene in Patients With Alcohol Dependence
Alcohol Dependence
Primary: Change From Baseline in the Monthly Number of Heavy Drinking Days (HDDs) — -8.91; -11.24 days — p=0.002
Phase 3 N=36 Safety and Efficacy Study of Bimatoprost in Japanese Patients With Chemotherapy-Induced Eyelash Hypotrichosis
Eyelash Hypotrichosis
Primary: Percentage of Participants With at Least a 1-Grade Increase in Overall Eyelash Prominence Using the Global Eyelash Assessment Scale (GEA) — 88.9; 27.8 Percentage of…
Phase 2 N=101 Topical Tranexamic Acid and Acute Blood Loss in Total Knee Arthroplasty
Acute Blood Loss Anemia · Osteoarthritis, Knee
Primary: Blood Loss — 1293.1; 940.2 mL
Phase 3 N=671 S0124: Cisplatin Combined With Irinotecan or Etoposide For Extensive-Stage Small Cell Lung Cancer
Lung Cancer
Primary: Overall Survival — 9.9; 9.1 Months
Phase 3 N=173 Safety and Efficacy Study of Bimatoprost in Japanese Patients With Eyelash Hypotrichosis
Eyelash Hypotrichosis
Primary: Percentage of Participants With at Least a 1-Grade Increase in Overall Eyelash Prominence Using the Global Eyelash Assessment Scale (GEA) — 77.3; 17.6 Percentage of…
Phase 2 N=59 GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients
Amenorrhea · Premature Ovarian Failure · Ovarian Function Insufficiency
Primary: Number of Participants With Secondary Amenorrhea Following 3-month Depot Leuprolide — 37 participants
Phase 2 N=82 Rituximab and ABVD for Hodgkin's Patients
Lymphoma
Primary: 5-year Failure-free Survival Rate for Participants With Hodgkin's Disease Given Rituximab With ABVD — 83 percentage of participants
Phase 3 N=123 Safety and Efficacy of CJ-50300 in Healthy Volunteers
Smallpox
Primary: Cutaneous Take Reaction — 81; 41 participants
Phase 3 N=718 Efficacy of Nalmefene in Patients With Alcohol Dependence
Alcohol Dependence
Primary: Change From Baseline in the Monthly Number of Heavy Drinking Days (HDDs) — -10.58; -12.30 days — p=0.012
Phase 2 N=101 A Comfort Study of Brinzolamide 1% / Brimonidine 0.2% Fixed Combination, Brinzolamide 1% and Brimonidine 0.2%
Open-Angle Glaucoma · Ocular Hypertension
Primary: Mean Ocular Discomfort Score — 0.8; 0.4; 0.3 Units on a scale
Phase 2 N=34 Alteration in Timing of Plerixafor Administration
Autologous Transplantation
Primary: Number of Patients Who Collected ≥ 6 x 10^6 CD34+ Cells by Day 5 (4 Apheresis Sessions) With Plerixafor Administration at 1500. — 31 Participants
Phase 3 N=1,454 Sodium Hyaluronate Ophthalmic Solution, 0.18% for Treatment of Dry Eye Syndrome
Dry Eye Syndrome
Primary: Change From Baseline in Lissamine Green Staining (LGS) Total Score at Day 7 — 4.9; 4.8; -0.8; -0.7 Units on a scale
N/A N=452 The INFUSE - Anterior Myocardial Infarction (AMI) Study
Acute Anterior Myocardial Infarction
Primary: Primary Endpoint - Infarct Size at 30 Days as a Percentage of Total Left Ventricular Mass - Abciximab Infusion vs. No Infusion — 15.1; 17.9; 17.2 Percentage of Left…
Phase 1 N=12 Evaluation of the Glucoregulatory Effects of Glucagon-like Peptide-1 Receptor (GLP-1 Receptor) Activation in Participants With Type 2 Diabetes Mellitus (MK-0000-222)
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Time-weighted Average of Glucose Measured by Area Under the Curve (AUC) After a Single Dose of Oxyntomodulin (OXM) — 106.3; 122.6 mg/dL — p=0.024